465 related articles for article (PubMed ID: 22634722)
1. Expanding the clinical indications for α(1)-antitrypsin therapy.
Lewis EC
Mol Med; 2012 Sep; 18(1):957-70. PubMed ID: 22634722
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic compositions and uses of alpha1-antitrypsin: a patent review (2012 - 2015).
Lior Y; Geyra A; Lewis EC
Expert Opin Ther Pat; 2016 May; 26(5):581-9. PubMed ID: 26966859
[TBL] [Abstract][Full Text] [Related]
3. Augmentation therapy with alpha1-antitrypsin: novel perspectives.
Sabina J; Tobias W
Cardiovasc Hematol Disord Drug Targets; 2013 Aug; 13(2):90-8. PubMed ID: 23987997
[TBL] [Abstract][Full Text] [Related]
4. Alpha-1 Antitrypsin Therapy in Cystic Fibrosis and the Lung Disease Associated with Alpha-1 Antitrypsin Deficiency.
McElvaney NG
Ann Am Thorac Soc; 2016 Apr; 13 Suppl 2():S191-6. PubMed ID: 27115956
[TBL] [Abstract][Full Text] [Related]
5. Alpha-1 antitrypsin augmentation therapy.
Wewers MD; Crystal RG
COPD; 2013 Mar; 10 Suppl 1():64-7. PubMed ID: 23527997
[TBL] [Abstract][Full Text] [Related]
6. Emphysema in alpha1-antitrypsin deficiency: does replacement therapy affect outcome?
Abboud RT; Ford GT; Chapman KR
Treat Respir Med; 2005; 4(1):1-8. PubMed ID: 15725045
[TBL] [Abstract][Full Text] [Related]
7. Aralast: an alpha 1-protease inhibitor for the treatment of alpha-antitrypsin deficiency.
Mordwinkin NM; Louie SG
Expert Opin Pharmacother; 2007 Oct; 8(15):2609-14. PubMed ID: 17931094
[TBL] [Abstract][Full Text] [Related]
8. Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19.
Bai X; Hippensteel J; Leavitt A; Maloney JP; Beckham D; Garcia C; Li Q; Freed BM; Ordway D; Sandhaus RA; Chan ED
Med Hypotheses; 2021 Jan; 146():110394. PubMed ID: 33239231
[TBL] [Abstract][Full Text] [Related]
9. Commercial α1-antitrypsin preparations markedly differ in their potential to inhibit the ATP-induced release of monocytic interleukin-1β.
Agné A; Richter K; Padberg W; Janciauskiene S; Grau V
Pulm Pharmacol Ther; 2021 Jun; 68():102020. PubMed ID: 33774155
[TBL] [Abstract][Full Text] [Related]
10. Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency.
Tirado-Conde G; Lara B; Miravitlles M
Ther Adv Respir Dis; 2008 Feb; 2(1):13-21. PubMed ID: 19124355
[TBL] [Abstract][Full Text] [Related]
11. alpha1-Antitrypsin deficiency: best clinical practice.
Kalsheker NA
J Clin Pathol; 2009 Oct; 62(10):865-9. PubMed ID: 19783716
[TBL] [Abstract][Full Text] [Related]
12. Alpha-1 Antitrypsin Substitution for Extrapulmonary Conditions in Alpha-1 Antitrypsin Deficient Patients.
Baranovski BM; Schuster R; Nisim O; Brami I; Lior Y; Lewis EC
Chronic Obstr Pulm Dis; 2018 Sep; 5(4):267-276. PubMed ID: 30723784
[TBL] [Abstract][Full Text] [Related]
13. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ).
Hill AT; Campbell EJ; Bayley DL; Hill SL; Stockley RA
Am J Respir Crit Care Med; 1999 Dec; 160(6):1968-75. PubMed ID: 10588615
[TBL] [Abstract][Full Text] [Related]
14. Aralast: a new alpha1-protease inhibitor for treatment of alpha-antitrypsin deficiency.
Louie SG; Sclar DA; Gill MA
Ann Pharmacother; 2005 Nov; 39(11):1861-9. PubMed ID: 16219903
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema.
Blanco I; Lara B; de Serres F
Orphanet J Rare Dis; 2011 Apr; 6():14. PubMed ID: 21486454
[TBL] [Abstract][Full Text] [Related]
16. Diabetic retinopathy: could the alpha-1 antitrypsin be a therapeutic option?
Ortiz G; Salica JP; Chuluyan EH; Gallo JE
Biol Res; 2014 Nov; 47():58. PubMed ID: 25723058
[TBL] [Abstract][Full Text] [Related]
17. Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications.
Chapman KR; Chorostowska-Wynimko J; Koczulla AR; Ferrarotti I; McElvaney NG
Int J Chron Obstruct Pulmon Dis; 2018; 13():419-432. PubMed ID: 29430176
[TBL] [Abstract][Full Text] [Related]
18. Augmentation therapy for alpha(1)-antitrypsin deficiency.
Juvelekian GS; Stoller JK
Drugs; 2004; 64(16):1743-56. PubMed ID: 15301559
[TBL] [Abstract][Full Text] [Related]
19. Acute-phase protein α1-anti-trypsin: diverting injurious innate and adaptive immune responses from non-authentic threats.
Guttman O; Baranovski BM; Schuster R; Kaner Z; Freixo-Lima GS; Bahar N; Kalay N; Mizrahi MI; Brami I; Ochayon DE; Lewis EC
Clin Exp Immunol; 2015 Feb; 179(2):161-72. PubMed ID: 25351931
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of inhaled human α-1 antitrypsin in people with α-1 antitrypsin deficiency-related emphysema.
Franciosi AN; McCarthy C; McElvaney NG
Expert Rev Respir Med; 2015 Apr; 9(2):143-51. PubMed ID: 25598013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
